Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Ocular Inflammation

  • Home
  • Ocular Inflammation
Ocular Inflammation Linked to Higher Risk of Anti-Adalimumab Antibodies in Autoimmune Disease Patients
Posted innews Ophthalmology Rheumatology

Ocular Inflammation Linked to Higher Risk of Anti-Adalimumab Antibodies in Autoimmune Disease Patients

Posted by MedXY By MedXY 05/29/2026
Ocular inflammation was linked to a higher risk of anti-adalimumab antibody formation in patients treated with adalimumab. More than 20% developed antibodies, supporting closer monitoring and therapeutic drug testing in high-risk patients.
Read More
Clobetasol Propionate Ophthalmic Suspension 0.05%: A New Therapeutic Milestone in Post-Cataract Surgery Inflammation and Pain Management
Posted inClinical Updates news Ophthalmology

Clobetasol Propionate Ophthalmic Suspension 0.05%: A New Therapeutic Milestone in Post-Cataract Surgery Inflammation and Pain Management

Posted by MedXY By MedXY 05/11/2026
This review synthesizes clinical evidence for CPN 0.05% (BYQLOVI®), highlighting its rapid efficacy, superior pain resolution, and favorable safety profile compared to traditional ocular steroids following cataract surgery.
Read More
  • Team Behavior and Patient Outcome Changes Following Human Factors Training in Pediatric Airway Endoscopy: A Review of Evidence and Clinical Implications
  • Longitudinal Voice Changes in Transmasculine Adolescents and Young Adults Undergoing Testosterone Therapy: Insights from a Prospective Cohort Study
  • Expedited Discharge After Isolated Coronary Artery Bypass Grafting: Impacts on Hospital Stay and Patient Outcomes
  • Genomic Profiling of Primary Gastric Tumors Predicts Recurrence Patterns and Survival Outcomes
  • Robotic Whole-Graft Liver Transplantation: Insights from 45 Cases and Benchmark Outcome Analysis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in